MAP2K7 and melanoma: While the use of a single cell line (A375) is a limitation, similar trends have been reported in WM115 and M14 melanoma models, supporting the generalizability of these observations (50).Additionally, recent reports, including data referenced in registered patents and conference abstracts, have identified resistance to BRAF/MEK inhibitors such as encorafenib/binimetinib as a persistent challenge in the treatment of BRAF-mutant melanoma (51, 52).